These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3485230)

  • 1. [New clues to the etiology of Parkinson disease: parkinsonism induced by the neurotoxin MPTP].
    Jonsson G; Sundström E
    Lakartidningen; 1986 Jan; 83(4):215-8. PubMed ID: 3485230
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pethidine and parkinsonism. 1-Metyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a new neurotoxin].
    Hunskår S
    Tidsskr Nor Laegeforen; 1986 Jan; 106(3):219-20. PubMed ID: 3485316
    [No Abstract]   [Full Text] [Related]  

  • 3. Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.
    Knaryan VH; Samantaray S; Varghese M; Srinivasan A; Galoyan AA; Mohanakumar KP
    Neuropeptides; 2006 Aug; 40(4):291-8. PubMed ID: 16712929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanism of induction of parkinsonism by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin].
    Hirata Y; Nagatsu T
    Tanpakushitsu Kakusan Koso; 1986 Apr; 31(5):398-409. PubMed ID: 3520683
    [No Abstract]   [Full Text] [Related]  

  • 5. The neurochemical and clinical effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in small animals.
    Donnan GA; Kaczmarczyk SJ; Solopotias T; Rowe P; Kalnins RM; Vajda FJ; Mendelsohn FA
    Clin Exp Neurol; 1986; 22():155-64. PubMed ID: 3495376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
    Matsubara K
    Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional recovery in parkinsonian monkeys treated with GDNF.
    Gash DM; Zhang Z; Ovadia A; Cass WA; Yi A; Simmerman L; Russell D; Martin D; Lapchak PA; Collins F; Hoffer BJ; Gerhardt GA
    Nature; 1996 Mar; 380(6571):252-5. PubMed ID: 8637574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl)pyridine: studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Finnegan KT; Irwin I; Delanney LE; Ricaurte GA; Langston JW
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1144-51. PubMed ID: 3498815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MPTP: a pharmacological tool to study parkinsonism.
    Kulkarni SK; Mehta AK; Aley KO; Shukla VK
    Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
    Rajeswari A; Sabesan M
    Inflammopharmacology; 2008 Apr; 16(2):96-9. PubMed ID: 18408903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Etiopathogeny of Parkinson disease. The MPTP revolution].
    Sampaio C; Castro Caldas A
    Acta Med Port; 1988; 1(4-6):304-7. PubMed ID: 3073646
    [No Abstract]   [Full Text] [Related]  

  • 13. The MPTP model of Parkinson's disease.
    Smeyne RJ; Jackson-Lewis V
    Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multipoint analysis of reduced (125)I-meta-iodobenzylguanidine uptake and norepinephrine turnover in the hearts of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine-induced parkinsonism.
    Fukumitsu N; Suzuki M; Fukuda T; Kiyono Y
    Nucl Med Biol; 2009 Aug; 36(6):623-9. PubMed ID: 19647168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Sayre LM
    Toxicol Lett; 1989 Aug; 48(2):121-49. PubMed ID: 2672418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [L-threo-DOPS therapy and parkinsonism].
    Narabayashi H
    No To Shinkei; 1986 Jan; 38(1):60-2. PubMed ID: 3083844
    [No Abstract]   [Full Text] [Related]  

  • 17. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
    Boireau A; Dubédat P; Bordier F; Peny C; Miquet JM; Durand G; Meunier M; Doble A
    Neuroreport; 1994 Dec; 5(18):2657-60. PubMed ID: 7696626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M
    J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease.
    Liberatore GT; Jackson-Lewis V; Vukosavic S; Mandir AS; Vila M; McAuliffe WG; Dawson VL; Dawson TM; Przedborski S
    Nat Med; 1999 Dec; 5(12):1403-9. PubMed ID: 10581083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
    Prediger RD; Rial D; Medeiros R; Figueiredo CP; Doty RL; Takahashi RN
    Ann N Y Acad Sci; 2009 Jul; 1170():629-36. PubMed ID: 19686204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.